Originally published In Press as doi:10.1074/jbc.M110496200 on February 7, 2002
J. Biol. Chem., Vol. 277, Issue 18, 15252-15260, May 3, 2002
Flavonoid Inhibition of Sodium-dependent Vitamin C
Transporter 1 (SVCT1) and Glucose Transporter Isoform 2 (GLUT2),
Intestinal Transporters for Vitamin C and Glucose*
Jian
Song
,
Oran
Kwon
,
Shenglin
Chen
,
Rushad
Daruwala
,
Peter
Eck
,
Jae B.
Park§, and
Mark
Levine
¶
From the
Molecular and Clinical Nutrition Section,
Digestive Diseases Branch, NIDDK, National Institutes of Health,
Bethesda, Maryland 20892-1372 and the § Phytonutrients
Laboratory, Beltsville Human Nutrition Research Center, U. S. Department of Agriculture, Beltsville, Maryland 20705
Received for publication, November 1, 2001, and in revised form, January 22, 2002
 |
ABSTRACT |
Vitamin C and flavonoids, polyphenols with
uncertain function, are abundant in fruits and vegetables. We
postulated that flavonoids have a novel regulatory action of delaying
or inhibiting absorption of vitamin C and glucose, which are
structurally similar. From six structural classes of flavonoids, at
least 12 compounds were chosen for studies. We investigated the effects
of selected flavonoids on the intestinal vitamin C transporter SVCT1(h)
by transfecting and overexpressing SVCT1(h) in Chinese hamster ovary
cells. Flavonoids reversibly inhibited vitamin C transport in
transfected cells with IC50 values of 10-50
µM, concentrations expected to have physiologic
consequences. The most potent inhibitor class was flavonols, of which
quercetin is most abundant in foods. Because Chinese hamster ovary
cells have endogenous vitamin C transport, we expressed SVCT1(h) in
Xenopus laevis oocytes to study the mechanism of transport
inhibition. Quercetin was a reversible and non-competitive inhibitor of
ascorbate transport; Ki 17.8 µM.
Quercetin was a potent non-competitive inhibitor of GLUT2 expressed in
Xenopus oocytes; Ki 22.8 µM. When diabetic rats were administered glucose with
quercetin, hyperglycemia was significantly decreased compared with
administration of glucose alone. Quercetin also significantly decreased
ascorbate absorption in normal rats given ascorbate plus quercetin
compared with rats given ascorbate alone. Quercetin was a specific
transport inhibitor, because it did not inhibit intestinal sugar
transporters GLUT5 and SGLT1 that were injected and expressed in
Xenopus oocytes. Quercetin inhibited but was not
transported by SVCT1(h). Considered together, these data show that
flavonoids modulate vitamin C and glucose transport by their respective
intestinal transporters and suggest a new function for flavonoids.
 |
INTRODUCTION |
Flavonoids are polyphenols that are widely distributed in plant
foods and ingested by humans. Flavonoids are subdivided into six
structural classes, flavones, flavonols, flavanones, isoflavones, anthocyanidins, and catechins. Although some flavonoids have been proposed to be antioxidants, flavonoid function in vivo is
uncertain (1, 2).
The flavonoid-like compound phloretin was utilized more than four
decades ago to inhibit sodium-independent glucose transport (3).
Structural analogs of phloretin from the flavonoid classes of
flavanones and flavones inhibited sodium-independent glucose efflux
from intestinal cells but not sodium-dependent glucose uptake (4). Because glucose is structurally similar to ascorbic acid
(ascorbate, vitamin C) and especially to its oxidized product dehydroascorbic acid (5-7), more recent reports describe effects of
flavonoids on ascorbate, dehydroascorbic acid, and glucose transport.
The flavonol quercetin and the isoflavone genistein at relatively high
concentrations of 100 µM decreased ascorbate transport in
three intestinal cell lines (8). The isoflavone genistein but not the
related isoflavone daidzein inhibited glucose and dehydroascorbic acid
transport in leukemic (HL-60) cells (9). Inhibition of glucose
transport by genistein was competitive and occurred in cells
overexpressing GLUT1.1 In
other experiments several flavonoid classes inhibited transport of
glucose, dehydroascorbic acid, and ascorbate in three leukemic cell
types, the most potent inhibition occurring with flavonols, and the
effects could not be explained by ascorbate oxidation (10, 11). Glucose
and dehydroascorbic acid transport were inhibited competitively, and
ascorbate transport was inhibited non-competitively.
Some aspects of the reported effects of flavonoids on transport
inhibition are generally consistent given the structural similarities of glucose, dehydroascorbic acid, and ascorbic acid. However, some
reported findings are surprising because of the distinct transport
mechanisms for these substrates. Glucose is transported by facilitated
sodium-independent glucose transporters GLUT1-GLUT4, GLUT6, GLUT8 and
by sodium-dependent transporters SGLT1 and SGLT2 (12-18).
Dehydroascorbic acid transport is sodium-independent and is mediated by
only GLUT1, GLUT3, and GLUT4 (19-21). No glucose transporters
transport ascorbate (20). Ascorbate transport is sodium-dependent and is mediated by ascorbate transporters
SVCT1 and SVCT2, neither of which transport glucose and dehydroascorbic acid (22, 23).
By coupling these transport mechanisms and the observations that
flavonoids inhibited several distinct cellular transport activities,
new insights into flavonoid function become possible. The physiologic
implications of the inhibitory effects of flavonoids on transport were
not previously apparent. This is because inhibitory effects of
flavonoids on cellular transport occurred at concentrations of 15-100
µM (8-11), but peak concentrations of flavonoids in human plasma are ~1 µM after flavonoid ingestion (24,
25). We recognized, however, that flavonoid concentrations that inhibit glucose, ascorbate, and dehydroascorbic acid transport are expected in
the intestinal lumen (24, 26). We hypothesized that novel functions of
flavonoids may be to distribute nutrient absorption throughout small
intestine or to frankly inhibit absorption (11).
Because flavonoids inhibited transport of ascorbate, dehydroascorbic
acid, and glucose, the available data are consistent with the
possibility that flavonoids modulate some intestinal transporters (10,
11). Nevertheless, more compelling evidence for this hypothesis is
lacking. For ascorbate, the intestinal ascorbate transporter is SVCT1,
but some flavonoid effects were characterized using cells that express
SVCT2(11). In experiments with intestinal cell lines, it was not
certain whether flavonoid effects were because of inhibition of
dehydroascorbic acid transport or ascorbate transport or simply to
ascorbate loss (8). For glucose the intestinal transporters are GLUT2
and SGLT1(12, 27), and the GLUT isoform GLUT5 transports fructose only
(12), but these enteric transporters were not evaluated for flavonoid
effects (9, 10).
To address our hypothesis, in this paper we tested the effects of
flavonoids on the ascorbate intestinal transporter SVCT1(h) and the
sugar intestinal transporters GLUT2, GLUT5, and SGLT1. The data
indicate that flavonols, a flavonoid class abundant in plant foods
consumed by humans, are potent non-competitive and reversible
inhibitors of SVCT1(h) and GLUT2 at concentrations predicted from
dietary ingestion.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
[14C]Ascorbic acid (8 mCi/mmol)
2-[3H]deoxyglucose (25.5 Ci/mmol),
[14C]fructose (300 mCi/mmol), and
[14C]glucose (265 mCi/mmol) were purchased from
PerkinElmer Life Sciences. [14C]Quercetin (53 mCi/mmol)
was purchased from ChemSyn Laboratories (Lenexa, KS). Quercetin,
fisetin, myricetin, rutin, gossypin, apigenin, naringenin, naringin,
hesperetin, genistein, luteolin, daidzein, epicatechin, and catechin
were purchased from Sigma. Cyanidin, gossypetin, and delphinidin were
obtained from Indofine Chemical Co., Inc. (Somerville, NJ).
Cell Transfection and Culture--
CHO cells were obtained from
ATCC (Manassas, VA). The transfection construct was made by inserting
1797 base pairs of SVCT1(h) into pcDNA 6/V5-His C vector
(Invitrogen) between HindIII and EcoRI cloning
sites, in-frame with the C-terminal peptide. CHO cells were transfected
with the construct using LipofectAMINE PLUS kit (Invitrogen). One day
before transient transfection, CHO cells growing in Ham's F-12 medium
on 60-mm plates were incubated with 0.05% trypsin, EDTA (Invitrogen)
for 5 min and counted. 107 cells were re-plated on 60-mm
plates and achieved 50-90% confluency in 24 h in Ham's F-12
medium with 10% heat-inactivated fetal calf serum. Cells were then
washed once in phosphate-buffered saline, and 2 ml of Ham's F-12
medium without serum were added to each 60-mm plate. To prepare
transfection mixtures for each plate, 2 µg of DNA in 2 µl of
H2O were diluted into 240 µl of medium without serum and
8 µl of AMINE PLUS reagent. In a second tube, 12 µl of
LipofectAMINE PLUS reagent was diluted into 238 µl of medium without
serum. The two tubes were incubated for 15 min at room temperature,
combined, and incubated for an additional 15 min at room temperature.
The combined transfection mixture (500 µl) was added to each plate,
which was gently swirled and then incubated at 37 °C, 5%
CO2 atmosphere. After 3 h the medium was replaced with
Ham's F-12 medium with 10% fetal bovine serum. Transiently
transfected cells were used in experiments in 24-48 h.
The reporter gene V5 in the pcDNA 6/V5-His C vector was used to
monitor transfection efficiency in transiently transfected cells.
Plated cells 24 h after transfection were fixed for 15 min in 1%
freshly prepared paraformaldehyde in phosphate-buffered saline. Cells
were washed three times with phosphate-buffered saline, permeabilized
for 5 min in 0.2% Triton X-100 in phosphate-buffered saline, and
incubated for 30 min in phosphate-buffered saline containing 1% bovine
serum albumin (blocking buffer). Cells were then incubated for 1 h
with anti-V5 mouse antibody diluted 1:200 in blocking buffer. Cells
were washed three times with phosphate-buffered saline and incubated
for 1 h with secondary anti-mouse rabbit antibody conjugated with
horseradish peroxidase. Cells were washed again three times with
phosphate-buffered saline and incubated for 20 min with
3-amino-9-ethylcarbazole and hydrogen peroxide (AEC + Chromogen System,
DAKO, Carpinteria, CA). Cells were rinsed for 5 min with
H2O, and stained cells were counted by microscopy. Using
the above conditions, transfection efficiency was 30-85%. Cells with
the highest transfection efficiency were used for transport experiments.
The blasticidin resistance site in the pcDNA 6/V5-His C vector was
used to develop stably transfected cells. Plated CHO cells transiently
transfected with SVCT1(h) as above were maintained in Ham's F-12
medium with 10% fetal calf serum and the antibiotic blasticidin (10 µg/ml) for 48 h. Cells were trypsinized as above and diluted to
1.5 cells/ml medium containing blasticidin. 0.2 ml of this medium were
added to each well of 96-well cluster plates. Wells with 1 cell were
verified by microscopy, marked, and incubated at 37 °C, 5%
CO2 for 2 weeks in the continuous presence of blasticidin. Single cells that developed into clusters were trypsinized as above,
transferred to 50-ml flasks, and grown in Ham's F-12 medium with
blasticidin. Cells were tested for ascorbic acid transport activity as
described below, and cells with the highest activity were used.
Inhibition of Ascorbic Acid Transport in Transfected CHO
Cells--
Transiently or stably transfected CHO cells in 24-well
plates were washed once and incubated with Krebs buffer 30 mmol/liter HEPES, 130 mmol/liter NaCl, 4 mmol/liter
KH2PO4, 1 mmol/liter MgSO4, 1 mmol/liter CaCl2, pH 7.4). Transport was initiated by adding [14C]ascorbic acid and flavonoids together at the
indicated concentrations for the times specified. Flavonoids were
diluted 1:100 from concentrated stock solutions prepared fresh by
dissolving flavonoids in Me2SO. Control cells were
incubated with [14C]ascorbic acid and 1%
Me2SO without flavonoids. After incubation at 37 °C,
uptake was stopped by washing cells in ice-cold phosphate-buffered saline. Cells were solubilized in PBS containing NaOH (0.1 mol/liter) and CHAPS (10 g/liter; J. T. Baker Inc.) and analyzed by
scintillation spectrometry or HPLC as described (28, 29). Data
displayed represent mean values ± S.D. of 3 replicates, and each
experiment was repeated a minimum of 3 times with similar results.
Error bars were omitted when the S.D. was less than symbol size.
Inhibition of Ascorbic Acid and Glucose Transport in Xenopus
laevis Oocytes--
X. laevis oocytes were isolated and
injected with cRNA coding for the ascorbic acid transporter SVCT1(h) or
glucose transporters GLUT2, GLUT5, or SGLT1 as described (20, 23).
Briefly, ovaries were resected from adult female frogs anesthetized
with 3-aminobenzoic acid ethyl ester (2 g/750 ml) (Sigma) in ice water.
Ovarian lobes were opened and incubated in 2 changes of OR-2 without
calcium (5 mM HEPES, 82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1 mM Na2HPO4, 100 µg/ml gentamicin,
pH 7.8) with collagenase (2 mg/ml) (Sigma) for 30 min each at 23 °C.
Individual oocytes (stages V and VI) were isolated from connective
tissue and vasculature, transferred to calcium-containing OR-2 (1 mM CaCl2), and maintained at 18-20 °C until
injection with cRNA. Oocytes were injected utilizing a Nanoject II
injector (Drummond Scientific, Broomall, PA). Injection volumes were
36.8 nl, and cRNA concentrations 1 ng/nl. Sham-injected oocytes were
injected with 36.8 nl of water. Post injection oocytes were maintained
at 18-20 °C until experiments were performed.
Two days post-injection, oocytes were equilibrated at room temperature
in OR-2. To begin experiments, flavonoids and
[14C]ascorbate or 2-[3H]deoxyglucose or
[14C]fructose or [14C]glucose were added
together at the indicated concentrations for the times specified.
Flavonoids in Me2SO were prepared as described for cells.
Control oocytes were incubated in substrate with 1% Me2SO
without flavonoids. After incubation at room temperature, oocytes were
washed four times with ice-cold phosphate-buffered saline. Individual
oocytes per replicate were solubilized with 10% SDS, and internalized
radioactivity was quantified by scintillation spectrometry as
pmol/oocyte. Each data point represents the mean value of 10-15
oocytes ± S.D. Each experiment was repeated a minimum of 3 times
with similar results. Error bars were omitted when the S.D. was less
than symbol size.
Effects of Quercetin in Rats--
Effects of quercetin on
hyperglycemia were tested using Zucker-fa/fa rats (Harlan
Sprague-Dawley, Indianapolis, IN). Rats were fed a diet providing
recommended allowances for all nutrients and were housed individually
in standard hanging stainless steel cages in an environmentally
controlled animal research facility maintained at 25 °C and 55%
relative humidity. For experiments, 5 rats 9-15 weeks old were fasted
overnight. The following morning a glucose solution of 2 g/kg of body
weight without quercetin was administered by oral drip. Blood samples
were collected by tail vein bleeding at 0, 15, 30, 45, and 60 min.
Glucose concentrations were immediately determined by glucometer (Dex,
Bayer Corp., Elkhart, IN). The experiment was repeated on the same rats
within 5 days using a glucose solution of 2 g/kg of body weight plus
quercetin, 3-65 mg/kg of body weight. Results were matched to each rat
in the presence and absence of quercetin. Each data point represents the mean of five animals ± S.E. Glucose with and without
quercetin was administered at least four times over 4 weeks to the same rats with similar results, and no animals became overtly ill or hypoglycemic. For time course experiments, the area under the curve was
determined for each condition, and the statistical significance was
calculated by two-tailed paired t test. For dose
experiments, data from the 30-min control time point (no quercetin)
were normalized to 100%. The effect of each quercetin dose at this
time point was expressed as percent after calculating as follows.
|
(Eq. 1)
|
Effects of quercetin on ascorbic acid absorption were studied in
normal CD (Sprague-Dawley) rats 12-15 weeks old with implanted carotid
artery catheters (Charles River Laboratories, Wilmington, MA).
Individual rats were housed and fed as described above. Before the
experiments, 10 rats were fasted overnight with access to water. To
begin experiments the following day, blood from arterial catheters as a
zero time value was drawn immediately before administration of the
experimental solution. Experimental solutions were fed by gavage and
contained either ascorbic acid alone 60 mg/kg of body weight or
ascorbic acid 60 mg/kg of body weight with quercetin 15 mg/kg of body
weight. Blood was drawn at 30, 60, 120, 180, and 240 min and placed on
ice for processing. The experiment was repeated on the same rats with
the alternate solution within 1 week. Arterial catheters were
maintained with heparinized solutions of glycerol and NaCl, and blood
was withdrawn according to the provider's recommendations. After 100 µl of blood was withdrawn and discarded, 100 µl of blood was
withdrawn and transferred to heparinized Microtainer tubes
(Becton Dickinson, Franklin Lakes, NJ). Catheters were flushed with 100 µl of heparinized NaCl solution after each blood withdrawal. Ascorbic
acid was analyzed as described (30). Each point represents the mean of
data from 10 animals ± S.E. Results were matched to each rat in
the presence and absence of quercetin. The area under the curve was
determined for each condition, and statistical significance was
calculated by two-tailed paired t test. Ascorbic acid with
or without quercetin was administered at least 3 times over 4 weeks to
the same rats with similar results.
 |
RESULTS |
Effect of Flavonoids on Ascorbate Transport in SVCT1(h)-transfected
Cells--
To study the effects of flavonoids on
sodium-dependent ascorbate transport, CHO cells were
transfected with SVCT1(h). Compared with vector-alone-transfected
cells, ascorbate transport increased 5-6-fold over 15 min in cells
stably transfected with SVCT1(h) (Fig.
1A). Increased transport was
linear for at least 15 min. Results were similar in transiently
transfected cells (not shown). Because of their abundance in foods, the
flavonoid quercetin and its glycone precursor rutin were tested for
their effects on ascorbate transport. Cells stably transfected with
SVCT1(h) were incubated with ascorbate 10-400 µM for 10 min with or without 50 µM quercetin, 50 µM
rutin, or sodium. Ascorbate transport was inhibited ~80% by
quercetin, virtually completely when sodium was replaced by choline,
and was unaffected by rutin (Fig. 1B). Again, results were
similar in transiently transfected cells (not shown). The findings
indicate that the flavonoid quercetin is a potent inhibitor of
ascorbate transport by SVCT1(h) in transiently or stably transfected cells. For consistency, stably transfected cells were used to characterize flavonoid effects.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 1.
Time course, concentration dependence, and
inhibition of ascorbic acid transport in stably transfected CHO
cells. A, time course of ascorbic acid transport in CHO
cells stably transfected with SVCT1(h). Confluent pcDNA 6/V5-His C
vector ( ) and SVCT1(h)-transfected CHO cells ( ) were incubated
with 300 µM [14C]ascorbic acid and 1%
Me2SO for different times at 37 °C. Cells were then
washed 4 times with 4 °C phosphate-buffered saline and solubilized
in NaOH (0.1 N), 1% CHAPS, and cell-associated
radioactivity was quantified. Data represent the mean ± S.D. See
methods for details. B, concentration dependence and
inhibition of ascorbic acid transport in CHO cells stably transfected
with SVCT1(h). Transport was initiated by adding
[14C]ascorbic acid at the indicated concentrations with
50 µM quercetin ( ) or 50 µM rutin ( )
or Me2SO (1%) alone ( ). Transport was also measured at
the indicated [14C]ascorbic acid concentrations with 1%
Me2SO in pcDNA 6/V5-His C vector-transfected CHO cells
( ) and in SVCT1(h)-transfected CHO cells with choline chloride
replacing sodium chloride ( ). After a 10-min incubation, cells were
washed, and transport was quantified as described in A and B and
"Experimental Procedures."
|
|
Flavonoids (Fig. 2A) consist
of a benzopyran configuration (rings A and C) linked to a benzene ring
(ring B). Variations in the heterocyclic C-ring and the linkage between
the benzopyran and benzene rings are the basis for classifying
flavonoids into six groups (31) (Fig. 2B). Within groups,
compounds can also be classified whether they are non-glycosylated
(aglycones) or glycosylated (glycones). Flavonoid groups and
representative aglycone compounds for each are: flavonol (quercetin,
rutin (glycone form of quercetin), myricetin, fisetin, gossypetin,
gossypin (glycone form of gossypetin); flavone (apigenin); flavanone
(naringenin, naringin (glycone form of naringenin)); isoflavone
(genistein, daidzein); catechin (catechin); and anthocyanin (cyanidin).
There are similarities between the chemical structure of ascorbate and some flavonoids, especially flavonols (Fig. 2C).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
Flavonoid structure and flavonoid
classes. A, flavonoids have benzopyran (rings
A and C) and benzene (ring B) moieties.
B, different flavonoid classes have variations in the C ring
and in the linkage between the benzopyran and benzene rings. Flavonoids
can have glycosylated and aglycone forms. Structures of each flavonoid
class are followed by examples of that class. See text for details.
Flavonols are quercetin, rutin, fisetin, myricetin, gossypetin, and
gossypin. Flavones are represented by apigenin. Flavanones are
naringenin and naringin. Isoflavones are genistein and daidzein.
Catechins are represented by catechin. Anthocyanins are represented by
cyanidin. C, structural similarities between quercetin and
ascorbic acid are circled.
|
|
Because quercetin was an effective inhibitor and is a flavonol, other
flavonols were tested for inhibition of ascorbate transport in cells
stably transfected with SVCT1(h). Fisetin, myricetin, and quercetin
each had a similar IC50 for transport inhibition (Fig.
3A, Table
I). Inhibition was eliminated if
glycosylated residues were present at the 3 or 8 positions (rutin and
gossypin, respectively) and when the hydrogen at the 8 position was
replaced with a hydroxyl group (gossypetin).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
Flavonoid inhibition of ascorbic acid
transport in SVCT1(h) stably transfected cells. CHO cells stably
transfected with SVCT1(h) were incubated with the indicated
concentrations of flavonoids and [14C]ascorbic acid 300 µM in 1% Me2SO for 5 min. Cells were washed
and transport quantified as in Fig. 1. A, incubation with
flavonoids from the flavonol class. , rutin; , quercetin; ,
myricetin; , fisetin; , gossypetin; , gossypin. B,
incubation with compounds from different flavonoid classes. Flavonol
class ( , quercetin; , rutin); flavone class (×, apigenin);
flavanone class ( , naringenin; , naringin; isoflavone class ( ,
genistein); catechin class ( , catechin); anthocyanin class ( ,
cyanidin).
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Flavonoid concentration inhibiting ascorbic acid transport by 50%
(IC50) in SVCT1(h)-transfected CHO cells
NI, not inhibitory.
|
|
Compounds in other flavonoid groups were tested for inhibition of
transport. The tested compounds in rank of most to least inhibitory
were myricetin > quercetin > fisetin = apigenin > genistein > naringenin > cyanidin >>>
naringin = catechin = rutin = gossypin = gossypetin
(Fig. 3, A and B, Table I). The data in Figs. 2 and 3 suggest that inhibition of SVCT1(h) by flavonoids is affected by
the presence of a double bond at C2-C3 and a ketone at C4 and that
these moieties confer structural similarity to ascorbate (Fig. 2,
A and C). Inhibition of transport was also
eliminated by substitution of the hydrogen at C8 and by glycosylation
at C3 or C8 (see Fig. 2A).
We tested other possibilities to explain flavonoid inhibition of
ascorbate transport. To test reversibility, cells were preincubated with quercetin 100 µM under the conditions that inhibited
ascorbate transport, washed, and incubated with ascorbate without
quercetin. Inhibition of transport was entirely reversible. Ascorbate
transport without quercetin preincubation was 4.4 nmol/10 min/mg of
protein and, with quercetin preincubation and washing, was 4.3 nmol/10 min/mg of protein. Without Me2SO, transport was 4.2 nmol/10
min/mg of protein, indicating that Me2SO alone did not
inhibit cellular transport. HPLC ascorbate analyses showed that
ascorbic acid concentrations were unchanged in the presence of
quercetin 100 µM, indicating that the transport findings
could not be explained by ascorbate oxidation by quercetin (32) (not shown).
Effect of Flavonoids on Ascorbic Acid Uptake in SVCT1(h)-injected
Oocytes--
To determine the kinetics mechanism of ascorbate
inhibition of SVCT1(h), it was necessary to utilize a system that
expressed only SVCT1(h). CHO cells had basal ascorbate transport (Fig.
1, A and B). Using reverse transcription-PCR,
SVCT2 but not SVCT1 was detected in CHO cells (not shown). Endogenous
SVCT2 would interfere with accurate determination of inhibition
kinetics of flavonoids with respect to SVCT1. Because X. laevis oocytes are not expected to transport ascorbate basally
(23), we used the oocyte expression system to characterize inhibition
kinetics of flavonoids on SVCT1(h).
The time course and concentration dependence of ascorbate transport
were determined in X. laevis oocytes injected with cRNA for
SVCT1(h) (Fig. 4). Ascorbate transport
was linear for at least 20 min, and sham-injected oocytes did not
transport ascorbate. Using an ascorbate incubation time of 5 min, the
Km of SVCT1(h) was 149 µM, similar to
previous values (23).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Concentration dependence of ascorbic acid
uptake in SVCT1(h)-injected oocytes. SVCT1(h) cRNA-injected
oocytes ( ) and sham-injected oocytes ( ) were incubated with
[14C]ascorbate 0-800 µM in 1%
Me2SO for 5 min. Oocytes were washed, and transport was
quantified as noted under "Experimental Procedures."
Inset, time course of ascorbic acid uptake in
SVCT1(h)-injected oocytes. SVCT1(h) cRNA-injected oocytes ( ) and
sham-injected oocytes ( ) were incubated for 0-20 min at 23 °C
with [14C]ascorbic acid 300 µM in 1%
Me2SO. The x axis represents 0-20 min, and the
y axis represents 0-250 pmol/oocyte. Oocytes were washed,
and transport was quantified as noted under "Experimental
Procedures."
|
|
Oocytes injected with SVCT1(h) were incubated with 300 µM
ascorbate for 5 min with or without flavonols 5-100 µM
(Fig. 5A). Quercetin and
fisetin had an IC50 of 32 and 14 µM,
respectively, whereas rutin was not inhibitory. Using a fixed flavonoid
concentration of 50 µM, we tested the effect of each
flavonoid class on ascorbate transport (Fig. 5B). The data
show that flavonols were the most potent inhibitors of SVCT1(h)
expressed in oocytes. Ascorbate transport in oocytes (Fig.
5B) was inhibited by other flavonoids in a fashion generally
consistent with flavonoid inhibition in cells transfected with SVCT1(h)
(Fig. 3, A and B).

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 5.
Flavonoid inhibition of ascorbate transport
in SVCT1(h) cRNA-injected oocytes. A, injected oocytes
were incubated for 5 min with ascorbic acid 300 µM and
flavonols 5-100 µM. Controls were incubated with
ascorbic acid in buffer and 1% Me2SO without flavonol.
Flavonols used were rutin ( ), quercetin( ), and fisetin( ).
B, injected oocytes were incubated for 5 min with 50 µM indicated flavonoid and 300 µM
[14C]ascorbic acid. Oocytes were washed and transport
quantified as described under "Experimental Procedures." Controls
with 300 µM ascorbic acid with and without 1%
Me2SO (DMSO) are also shown. Bars
represent controls (filled bars) and the following flavonoid
classes (from left to right): flavonol
(quercetin, fisetin, myricetin, gossypetin, rutin, and gossypin)
(open bars), flavanone (hesperetin, naringenin, and
naringin), catechin (catechin and epicatechin), flavone (apigenin and
luteolin), isoflavone (genistein and daidzein), and anthocyanidin
(cyanidin and delphinidin).
|
|
Reversibility was tested of quercetin inhibition of SVCT1(h) expressed
in oocytes. Ascorbate transport with 300 µM ascorbate in
1% Me2SO was 126 pmol/10 min/oocyte; with 100 µM quercetin preincubation for 10 min and washing
followed by 300 µM ascorbate in 1% Me2SO
ascorbate transport was 117 pmol/10 min/oocyte; and with 300 µM ascorbate without Me2SO or quercetin
ascorbate transport was also 117 pmol/10 min/oocyte. These data
indicate the quercetin inhibition of SVCT1(h) was reversible and that
Me2SO did not inhibit transport.
Because SVCT1(h) was the only ascorbate transporter injected and
expressed in oocytes, and quercetin inhibition was reversible, inhibition kinetics could be determined. Oocytes injected with SVCT1(h)
were incubated with 50-800 µM ascorbate and 0-50
µM quercetin for 5 min. Quercetin inhibited ascorbate
transport noncompetitively; Ki 17.8 µM
(Fig. 6).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Kinetics of quercetin inhibition of ascorbic
acid transport in SVCT1(h) cRNA-injected oocytes.
[14C]Ascorbic acid 50,100, 200, 400, or 800 µM was added with 10 µM ( ), 20 µM ( ), or 50 µM ( ) quercetin or with
1% Me2SO without quercetin ( ). Oocytes were
incubated for 5 min, washed, and analyzed for transported
ascorbic acid as described under "Experimental Procedures."
Kinetics are displayed using Eadie-Hofstee transformation. V/S,
velocity/substrate concentration.
|
|
We attempted to determine whether SVCT1(h) transported quercetin.
Oocytes injected with SVCT1(h) and sham-injected oocytes were incubated
with [14C]quercetin (100 µM) to measure
uptake. SVCT1(h)-injected oocytes had quercetin uptake of 4.6 pmol/5
min/oocyte, and sham-injected oocytes had quercetin uptake of 4.0 pmol/5 min/oocyte. These data suggest that SVCT1(h) does not transport quercetin.
Effects of the Flavonol Quercetin on Intestinal Glucose
Transporters--
We investigated whether quercetin inhibited the
intestinal glucose transporter GLUT2. Oocytes were injected with GLUT2
and incubated with 2-[3H]deoxyglucose in the presence or
absence of quercetin 10 or 20 µM (Fig.
7). Glucose transport was inhibited
non-competitively; Ki 22.8 µM.
Inhibition of GLUT2-mediated transport activity in oocytes by 100 µM quercetin was reversible (not shown).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Kinetics of quercetin inhibition of
2-deoxyglucose transport in GLUT2 cRNA-injected oocytes.
[3H]2-Deoxyglucose 2.5, 5.0, 7.5, 10, 20, or 40 mM was added with quercetin 10 µM ( ) or 20 µM ( ), or with 1% Me2SO without quercetin
( ). Oocytes were incubated for 5 min, washed, and analyzed for
transported 2-deoxyglucose as described in "Experimental
Procedures." Kinetics are displayed using Eadie-Hofstee
transformation. V/S, velocity/substrate concentration.
|
|
The effect of quercetin was tested on the other intestinal sugar
transporters GLUT5 and SGLT1. Oocytes injected with GLUT5 were
incubated with [14C]fructose (100 µM), the
substrate for GLUT5, with or without quercetin 100 µM.
Without quercetin, fructose transport was 4.6 pmol/10 min/oocyte, with
quercetin, fructose transport was 4.2 pmol/10 min/oocyte, and in
sham-injected oocytes, fructose transport was 0.2 pmol/10 min/oocyte.
These data indicate that quercetin did not inhibit fructose transport
by GLUT5. Similar experiments were performed with SGLT1 expressed in
oocytes. Transport of [14C]glucose 1 mM was
~200 pmol/10 min/oocyte and was unchanged by quercetin 5-100
µM. Thus, quercetin did not inhibit glucose transport by
SGLT1. Taken together, these data suggest that quercetin inhibition of
SVCT1 and GLUT2 is not mediated by general nonspecific effects on
transmembrane transport proteins.
Effects of Quercetin on Glucose and Ascorbic Acid Absorption in
Rats--
GLUT 2 has been suggested to be the major intestinal glucose
transporter under physiologic conditions (27, 33, 34). To test the
physiologic relevance of the effects of quercetin on glucose
absorption, the effects of quercetin were tested in diabetic Zucker
fa/fa rats. Animals fed glucose without quercetin were hyperglycemic,
with plasma glucose values approaching 300 mg/dl 30 min after glucose
ingestion (Fig. 8A). When
quercetin was ingested with glucose, hyperglycemia was significantly
decreased (p = 0.015). These data suggest that
quercetin might inhibit glucose absorption via GLUT2 in
vivo. The effect of quercetin on hyperglycemia was
dose-dependent (Fig. 8B).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 8.
Effects of quercetin on glucose absorption in
diabetic rats. A, Zucker fa/fa rats fasted overnight
were fed glucose solution (2 g/kg of body weight) with ( ) or without
( ) quercetin (60 mg/kg of body weight). Blood glucose values (mg/dl)
were determined by glucometer at the indicated times. Data from each
rat in the presence and absence of quercetin were matched.
n = 5, p = 0.015. B, Zucker
fa/fa rats fasted overnight were fed glucose solution (2 g/kg of body
weight) with or without quercetin 3-65 mg/kg/body weight. Blood
glucose values from the 30-min time point were determined by glucometer
and matched for each rat in the presence and absence of quercetin.
Glucose values without quercetin (control) were normalized to 100%,
and values in the presence of quercetin are expressed as % control.
n = 5.
|
|
Ascorbate absorption from the gastrointestinal tract is difficult
to demonstrate in experimental animals (35, 36). One explanation is
that during blood procurement hemolysis occurs, resulting in ascorbate
oxidation. To address this problem, absorption experiments were
performed on normal rats that had arterial catheters implanted to
facilitate blood withdrawal without hemolysis. When ascorbate was
administered by gavage to normal rats, blood ascorbate concentrations
increased ~45% and were sustained for 240 min. When quercetin and
ascorbate were administered together, quercetin significantly decreased
ascorbate absorption (p = 0.025) (Fig. 9). These data suggest that quercetin may
inhibit ascorbate intestinal transport in vivo.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 9.
Effects of quercetin on ascorbic acid
absorption in normal rats. CD (Sprague-Dawley) rats after
overnight fasting received by gavage ascorbic acid 60 mg/kg of body
weight with ( ) or without ( ) quercetin (15 mg/kg of body weight).
Plasma ascorbic acid was determined by HPLC at the indicated times.
Data from each rat in the presence and absence of quercetin were
matched. n = 10, p = 0.025.
|
|
 |
DISCUSSION |
The data in this paper show that flavonols and other flavonoids
inhibited ascorbate transport by the intestinal transporter SVCT1(h).
Inhibition of SVCT1(h) was shown in transiently transfected cells,
stably transfected cells, and X. laevis oocytes. Using quercetin as a representative flavonol, inhibition occurred when ascorbate and quercetin were added simultaneously, was fully
reversible, and was non-competitive. Non-competitive inhibition is
consistent with flavonoid inhibition of ascorbate transport in myeloid
cell lines, where the relevant ascorbate transporter was most likely SVCT2 rather than SVCT1 (11, 37). Flavonoid inhibition could not be
explained by ascorbate oxidation, because quercetin did not decrease
ascorbate stability. The relevance of the findings was
strengthened by experimental results in normal rats, showing that
ascorbate absorption was significantly decreased in animals given
ascorbate and quercetin compared with animals given ascorbate alone.
Inhibition of ascorbate transport was dependent on flavonoid structure.
The flavonol quercetin was an effective inhibitor, whereas its
glycosylated precursor rutin was not. Myricetin and fisetin, other
non-glycosylated flavonols, were also effective inhibitors. Flavonoids
in foods are usually glycosylated (24). However, studies in human
subjects with ileostomies show that quercetin glucosides are
efficiently and possibly completely hydrolyzed to quercetin in the
small intestine, most likely in the intestinal lumen (26, 38). Thus,
quercetin and other flavonols should be available to inhibit ascorbate transport.
The data in this paper also indicate that quercetin inhibited
intestinal glucose transport. With expression of the intestinal glucose
transporter GLUT2 in X. laevis oocytes, quercetin
inhibition of glucose transport occurred when substrate and
inhibitor were added together, was reversible, and was non-competitive.
The intestinal fructose transporter GLUT5 and the intestinal
sodium-dependent glucose transporter SGLT1 were not
inhibited by quercetin. When glucose and quercetin were co-administered
orally in Zucker fa/fa rats, quercetin significantly blunted the
hyperglycemia that occurred when glucose was administered alone. The
most effective dose of quercetin tested was ~60 mg/kg of body weight,
equivalent to ~4 g for an adult human. However, the administered dose
of glucose to achieve hyperglycemia in rats was 2 g/kg of body weight,
approximately double the dose used in glucose tolerance testing in
humans. Therefore, it is possible that the quercetin dose/kg of body
weight needed to blunt hyperglycemia in humans might be lower than
reported here in rats. In long term toxicity experiments in rats and
hamsters, safe quercetin doses were at least 400 mg/kg/day and as high
as 4000 mg/kg/day (39). Quercetin doses of 4 g were administered to humans orally without side effects (39). Based on the data, it is
possible that the effects of quercetin might be relevant physiologically or for use in managing hyperglycemia (diabetes) (40).
The findings here raise new possibilities concerning flavonoids and
their functions and may have physiological implications. Although
flavonoid actions in vivo are unknown, they have been suggested to have broad antioxidant properties in humans (41). Flavonoids act as antioxidants at concentrations of 50 µM
and above (42-46). However, peripheral venous and portal vein
concentrations of flavonoids are usually 50-fold lower. After ingestion
of flavonoid-rich foods, plasma flavonoid concentrations peak at ~1
µM, usually 1-2 h after ingestion (24, 25, 47). Fasting
flavonoid concentrations are usually <0.5 µM. Most
flavonoids have a half-life of 1-2 h, except quercetin. Flavonoid
metabolites substantially increase the total antioxidant capacity of
plasma, but the physiologic meaning of total antioxidant capacity is
uncertain (24, 41). Although flavonoid metabolites could be systemic
antioxidants, it is unlikely that flavonoids themselves act this way,
implying that flavonoids may have other actions in vivo.
In cell lines, the flavonol myricetin inhibited ascorbate transport
with Ki of 14 µM, and other flavonols
had IC50 values of 16-40 µM (11). Although
these concentrations are not realistic systemically, some are realistic
as intestinal intraluminal concentrations. For example, dietary
ingestion of quercetin and its glycone forms can be as much as 80 mg
daily, and ingestion of total flavonoids can be as high as 130 mg daily
(48). With an intestinal luminal distribution volume of 1 liter
(24), glycone and aglycone quercetin concentrations may be as much as
200 µM. With deglycosylation, substantial concentrations
of flavonoids may be present (24, 26).
We propose that novel functions of flavonoids may be to distribute
nutrient absorption throughout small intestine or to frankly inhibit
absorption. Flavonoids in vivo might possibly delay
or inhibit ascorbate and glucose absorption by more than one pathway (Fig. 10). The data in this paper
suggest that flavonoids could inhibit transport of ascorbate and
glucose from the intestinal lumen into cells. For ascorbate, molecular
mechanisms of absorption are incompletely characterized (49). Ascorbate
must be transported across the luminal membrane of enterocytes but must
also exit enterocytes on the basolateral surface to reach the portal
venous system and the systemic circulation. Although SVCT1 is probably responsible for ascorbate transport into enterocytes from the intestinal lumen, it is unknown how ascorbate is translocated across
the enterocyte basolateral membrane to enter the portal venous system.
For glucose, emerging evidence implicates GLUT2 may be a major
transporter of glucose from the luminal surface as well as from the
basolateral surface (27, 33, 34). Thus, quercetin in the intestinal
lumen could possibly inhibit both ascorbate and glucose influx into
enterocytes. It is also possible that quercetin or its metabolites
transported into enterocytes could inhibit efflux of intracellular
ascorbate and glucose across the basolateral membrane. The mechanism of
transport of quercetin itself is unknown, and the data here indicate
that SVCT1(h) does not transport quercetin.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 10.
Physiologic significance of flavonoid
inhibition of ascorbic acid and glucose transport. As shown
schematically, ascorbic acid and glucose absorption occurs from the
left (intestinal lumen) to right (basolateral surface) side of an
enterocyte. Quercetin inhibition of ascorbic acid transporter SVCT1
( ) and glucose transporter GLUT 2 ( ) is shown at the enterocyte
luminal membrane (left side of figure). Quercetin
has no effect on SGLT1 ( ) and GLUT5 ( ). The following are not
certain (indicated by ?): mechanisms of quercetin entry and efflux;
whether quercetin or its metabolites or both exit the enterocyte at the
basolateral surface; mechanism of ascorbic acid efflux at the
basolateral surface; whether quercetin or its metabolites within the
enterocyte inhibit sugar or ascorbic acid efflux at the basolateral
membrane.
|
|
Flavonoid inhibition of enteric glucose and ascorbate transporters
might result in broadening of peak post-absorptive plasma concentrations or frank inhibition of absorption, with clinical implications for each possibility. For ascorbate, broader and flatter
peak post-absorptive plasma concentrations would result in less
ascorbate excretion and higher distribution throughout body water.
Frank inhibition of ascorbate absorption, as shown here in rats, would
result in higher intestinal intraluminal concentrations, which could
quench nitrosamines and other harmful oxidants (50-52). In either
case, ascorbate bioavailability would change, with consequences for
recommended dietary allowances of the vitamin (30, 53). For glucose,
rapid glucose absorption in normal people might result in sharp
fluctuations in blood glucose and resulting catecholaminergic hyperresponsiveness (54). In diabetics, rapid glucose absorption could
exacerbate hyperglycemia. Decreasing or broadening glucose absorption
can diminish these responses (40, 55). Animal data in this paper are
consistent with flavonoid inhibition of glucose and ascorbic acid
enteric transport in vivo. Studies of ascorbate absorption
in animals are limited because of relatively low intestinal absorption
of ascorbate (35, 36), lack of suitability of whole blood for rapid
ascorbate analysis, and especially because of difficulty in obtaining
plasma samples without hemolysis. The ascorbate absorption experiments
described in this paper were made possible by obtaining blood samples
from implanted carotid artery catheters, thereby minimizing hemolysis.
In contrast to animal experiments, testing the effects of flavonoids on
glucose and ascorbate absorption in humans should be straightforward
(30, 56), and oral quercetin in humans at gram doses is safe (39, 57,
58). Based on the available evidence, it may be worthwhile to undertake
clinical experiments to test the effects of flavonoids on ascorbate and
glucose absorption.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Bldg. 10, Rm.
4D52, MSC 1372 National Institutes of Health, Bethesda, MD 20892-1372. Tel.: 301-402-5588; Fax: 301-402-6436; E-mail: MarkL@intra.niddk.nih.gov.
Published, JBC Papers in Press, February 7, 2002, DOI 10.1074/jbc.M110496200
 |
ABBREVIATIONS |
The abbreviations used are:
GLUT, glucose
transporter isoform;
CHO, Chinese hamster ovary;
HPLC, high performance
liquid chromatography;
SGLT, sodium-dependent glucose
transporter;
SVCT1(h), sodium-dependent vitamin C transporter
1, human;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.
 |
REFERENCES |
| 1.
|
Brown, J. E.,
Khodr, H.,
Hider, R. C.,
and C., A.
(1998)
Biochem. J.
330,
1173-1178
|
| 2.
|
Bravo, L.
(1998)
Nutr. Rev.
56,
317-333[Medline]
[Order article via Infotrieve]
|
| 3.
|
Lefevre, P. G.,
and Marshall, J. K.
(1959)
J. Biol. Chem.
234,
3022-3026[Free Full Text]
|
| 4.
|
Kimmich, G. A.,
and Randles, J.
(1978)
Membr. Biochem.
1,
221-237[Medline]
[Order article via Infotrieve]
|
| 5.
|
Mann, G. V.,
and Newton, P.
(1975)
Ann. N. Y. Acad. Sci.
258,
243-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Washko, P.,
and Levine, M.
(1992)
J. Biol. Chem.
267,
23568-23574[Abstract/Free Full Text]
|
| 7.
|
Washko, P. W.,
Wang, Y.,
and Levine, M.
(1993)
J. Biol. Chem.
268,
15531-15535[Abstract/Free Full Text]
|
| 8.
|
Kuo, S. M.,
Morehouse, H. F., Jr.,
and Lin, C. P.
(1997)
Cancer Lett.
116,
131-137[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Vera, J. C.,
Reyes, A. M.,
Carcamo, J. G.,
Velasquez, F. V.,
Rivas, C. I.,
Zhang, R. H.,
Strobel, P.,
Iribarren, R.,
Scher, H. I.,
Slebe, J. C.,
and Golde, D. W.
(1996)
J. Biol. Chem.
271,
8719-8724[Abstract/Free Full Text]
|
| 10.
|
Park, E.,
Wagenbichler, P.,
and Elmadfa, I.
(1999)
Int. J. Vitam. Nutr. Res.
69,
396-402[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Park, J. B.,
and Levine, M.
(2000)
J. Nutr.
130,
1297-1302[Abstract/Free Full Text]
|
| 12.
|
Mueckler, M.
(1994)
Eur. J. Biochem.
219,
713-725[Medline]
[Order article via Infotrieve]
|
| 13.
|
Gould, G. W.,
and Holman, G. D.
(1993)
Biochem. J.
295,
329-341
|
| 14.
|
Ibberson, M.,
Uldry, M.,
and Thorens, B.
(2000)
J. Biol. Chem.
275,
4607-4612[Abstract/Free Full Text]
|
| 15.
|
Doege, H.,
Bocianski, A.,
Joost, H. G.,
and Schurmann, A.
(2000)
Biochem. J.
350,
771-776
|
| 16.
|
Doege, H.,
Schurmann, A.,
Bahrenberg, G.,
Brauers, A.,
and Joost, H. G.
(2000)
J. Biol. Chem.
275,
16275-16280[Abstract/Free Full Text]
|
| 17.
|
Lisinski, I.,
Schurmann, A.,
Joost, H. G.,
Cushman, S. W.,
and Al-Hasani, H.
(2001)
Biochem. J.
358,
517-522[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Hediger, M. A.,
and Rhoads, D. B.
(1994)
Physiol. Rev.
74,
993-1026[Free Full Text]
|
| 19.
|
Vera, J. C.,
Rivas, C. I.,
Zhang, R. H.,
Farber, C. M.,
and Golde, D. W.
(1994)
Blood
84,
1628-1634[Abstract/Free Full Text]
|
| 20.
|
Rumsey, S. C.,
Kwon, O., Xu, G. W.,
Burant, C. F.,
Simpson, I.,
and Levine, M.
(1997)
J. Biol. Chem.
272,
18982-18989[Abstract/Free Full Text]
|
| 21.
|
Rumsey, S. C.,
Daruwala, R., Al-,
Hasani, H.,
Zarnowski, M. J.,
Simpson, I. A.,
and Levine, M.
(2000)
J. Biol. Chem.
275,
28246-28253[Abstract/Free Full Text]
|
| 22.
|
Tsukaguchi, H.,
Tokui, T.,
Mackenzie, B.,
Berger, U. V.,
Chen, X.-Z.,
Wang, Y.,
Brubaker, R. F.,
and Hediger, M. A.
(1999)
Nature
399,
70-75[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Daruwala, R.,
Song, J.,
Koh, W. S.,
Rumsey, S. C.,
and Levine, M.
(1999)
FEBS Lett.
460,
480-484[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Scalbert, A.,
and Williamson, G.
(2000)
J. Nutr.
130 Suppl. 8,
2073S-2085S[Abstract/Free Full Text]
|
| 25.
|
Conquer, J. A.,
Maiani, G.,
Azzini, E.,
Raguzzini, A.,
and Holub, B. J.
(1998)
J. Nutr.
128,
593-597[Abstract/Free Full Text]
|
| 26.
|
Walle, T.,
Otake, Y.,
Walle, U. K.,
and Wilson, F. A.
(2000)
J. Nutr.
130,
2658-2661[Abstract/Free Full Text]
|
| 27.
|
Kellett, G. L.,
and Helliwell, P. A.
(2000)
Biochem. J.
350,
155-162
|
| 28.
|
Washko, P. W.,
Rotrosen, D.,
and Levine, M.
(1989)
J. Biol. Chem.
264,
18996-19002[Abstract/Free Full Text]
|
| 29.
|
Levine, M.,
Wang, Y.,
and Rumsey, S. C.
(1999)
Methods Enzymol.
299,
65-76[Medline]
[Order article via Infotrieve]
|
| 30.
|
Levine, M.,
Conry-Cantilena, C.,
Wang, Y.,
Welch, R. W.,
Washko, P. W.,
Dhariwal, K. R.,
Park, J. B.,
Lazarev, A.,
Graumlich, J.,
King, J.,
and Cantilena, L. R.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
3704-3709[Abstract/Free Full Text]
|
| 31.
|
Hollman, P. C.,
and Katan, M. B.
(1999)
Food Chem. Toxicol.
37,
937-942[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Long, L. H.,
Clement, M. V.,
and Halliwell, B.
(2000)
Biochem. Biophys. Res. Commun.
273,
50-53[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Helliwell, P. A.,
Richardson, M.,
Affleck, J.,
and Kellett, G. L.
(2000)
Biochem. J.
350,
149-154
|
| 34.
|
Helliwell, P. A.,
Richardson, M.,
Affleck, J.,
and Kellett, G. L.
(2000)
Biochem. J.
350,
163-169
|
| 35.
|
Bush, M. J.,
and Verlangieri, A. J.
(1987)
Res. Commun. Chem. Pathol. Pharmacol.
57,
137-140[Medline]
[Order article via Infotrieve]
|
| 36.
|
Verlangieri, A. J.,
Fay, M. J.,
and Bannon, A. W.
(1991)
Life Sci.
48,
2275-2281[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Wang, Y.,
Mackenzie, B.,
Tsukaguchi, H.,
Weremowicz, S.,
Morton, C. C.,
and Hediger, M. A.
(2000)
Biochem. Biophys. Res. Commun.
267,
488-494[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Olthof, M. R.,
Hollman, P. C.,
Vree, T. B.,
and Katan, M. B.
(2000)
J. Nutr.
130,
1200-1203[Abstract/Free Full Text]
|
| 39.
|
Lamson, D. W.,
and Brignall, M. S.
(2000)
Altern. Med Rev.
5,
196-208[Medline]
[Order article via Infotrieve]
|
| 40.
|
Mooradian, A. D.,
and Thurman, J. E.
(1999)
Drugs
57,
19-29[Medline]
[Order article via Infotrieve]
|
| 41.
|
Pietta, P. G.
(2000)
J. Nat. Prod. (Lloydia)
63,
1035-1042[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Zeng, L. H., Wu, J.,
Fung, B.,
Tong, J. H.,
Mickle, D.,
and Wu, T. W.
(1997)
Biochem. Cell Biol.
75,
717-720[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Skaper, S. D.,
Fabris, M.,
Ferrari, V.,
Dalle, C. M.,
and Leon, A.
(1997)
Free Radic. Biol. Med.
22,
669-678[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Noroozi, M.,
Angerson, W. J.,
and Lean, M. E.
(1998)
Am. J. Clin. Nutr.
67,
1210-1218[Abstract]
|
| 45.
|
Oldreive, C.,
Zhao, K.,
Paganga, G.,
Halliwell, B.,
and Rice-Evans, C.
(1998)
Chem. Res. Toxicol.
11,
1574-1579[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Vinson, J. A.
(1998)
Adv. Exp. Med. Biol.
439,
151-164[Medline]
[Order article via Infotrieve]
|
| 47.
|
Noteborn, H. P.,
Jansen, E.,
Benito, S.,
and Mengelers, M. J.
(1997)
Cancer Lett.
114,
175-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Hertog, M. G.,
Hollman, P. C.,
Katan, M. B.,
and Kromhout, D.
(1993)
Nutr. Cancer
20,
21-29[Medline]
[Order article via Infotrieve]
|
| 49.
|
Malo, C.,
and Wilson, J. X.
(2000)
J. Nutr.
130,
63-69[Abstract/Free Full Text]
|
| 50.
|
Correa, P.,
Malcom, G.,
Schmidt, B.,
Fontham, E.,
Ruiz, B.,
Bravo, J. C.,
Bravo, L. E.,
Zarama, G.,
and Realpe, J. L.
(1998)
Aliment. Pharmacol. Ther.
12, Suppl 1.,
73-82
|
| 51.
|
Vermeer, I. T.,
Moonen, E. J.,
Dallinga, J. W.,
Kleinjans, J. C.,
and van Maanen, J. M.
(1999)
Mutat. Res.
428,
353-361[Medline]
[Order article via Infotrieve]
|
| 52.
|
Hecht, S. S.
(1997)
Proc. Soc. Exp. Biol. Med.
216,
181-191[Abstract] |